Search strategy
This meta-analysis was undertaken according to the Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRISMA) statement guideline [11] and Cochrane handbook for systematic reviews of interventions[12]. Two independent authors systematically searched literature in online medical search engines including PubMed/Medline, Scopus and Google Scholar were searched for relevant articles published from inception until May 2020. Combination of both following MESH and non-MESH terms were used: (orlistat[MeSH Terms] OR Tetrahydrolipstatin[MeSH Terms] OR THLP[MeSH Terms] OR Tetrahydrolipastatin[MeSH Terms] OR Alli[MeSH Terms] OR Xenical[MeSH Terms] OR Roche brand of orlistat[Title/Abstract]) OR Hoffmann‐La Roche brand of orlistat[Title/Abstract]) AND (Uric acid[MeSH Terms] OR Acid, Uric[MeSH Terms] OR 2,6,8-Trihydroxypurine[MeSH Terms] OR Trioxopurine[MeSH Terms] OR Urate[MeSH Terms] OR Blood uric acid[Title/Abstract] OR Hyperuricemia[Title/Abstract] OR HU[Title/Abstract] OR Serum uric acid[Title/Abstract] OR SUA[Title/Abstract] OR High serum uric acid [Title/Abstract] OR HSUA level[Title/Abstract] OR UA[Title/Abstract]). The search was also completed by manual search of the references list of clinical trials and previous review articles to include other potentially eligible trials. Language restrictions (English) were applied in our search strategy. The PubMed’s e-mail alert service was also activated to find any new articles that might appear in this area after our primary search.